The agency on Friday described licensing the vaccine as “an important step toward relieving the burden of this deadly disease.” The Ebola vaccine was originally developed in Canada and is now marketed by Merck as Ervebo. More than 270,000 people in Africa have received it as officials try to stop Congo’s ongoing outbreak. A second vaccine made by Johnson & Johnson, which is not yet licensed, will soon be used in parts of Congo where Ebola is not actively spreading. Also Friday, the World Health Organization is convening a meeting to consider whether the epidemic in Congo should still be designated a global emergency.
European Medicines Agency recommends licensing Ebola vaccine.